IN2012DN00860A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00860A
IN2012DN00860A IN860DEN2012A IN2012DN00860A IN 2012DN00860 A IN2012DN00860 A IN 2012DN00860A IN 860DEN2012 A IN860DEN2012 A IN 860DEN2012A IN 2012DN00860 A IN2012DN00860 A IN 2012DN00860A
Authority
IN
India
Prior art keywords
ligand
conjugated
antibody
optionally
formula
Prior art date
Application number
Inventor
Heng Cheng
Qiang Cong
Sanjeev Gangwar
Qian Zhang
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of IN2012DN00860A publication Critical patent/IN2012DN00860A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Abstract

Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
IN860DEN2012 2009-08-03 2010-08-02 IN2012DN00860A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23093209P 2009-08-03 2009-08-03
US23288309P 2009-08-11 2009-08-11
PCT/US2010/044078 WO2011017249A1 (en) 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00860A true IN2012DN00860A (en) 2015-07-10

Family

ID=42782224

Family Applications (1)

Application Number Title Priority Date Filing Date
IN860DEN2012 IN2012DN00860A (en) 2009-08-03 2010-08-02

Country Status (29)

Country Link
US (6) US8394922B2 (en)
EP (1) EP2461830B1 (en)
JP (1) JP5859964B2 (en)
KR (1) KR101759359B1 (en)
CN (2) CN102725001B (en)
AR (1) AR077701A1 (en)
AU (1) AU2010279674B2 (en)
BR (1) BR112012002615A2 (en)
CA (1) CA2770042C (en)
CL (1) CL2012000302A1 (en)
CO (1) CO6501196A2 (en)
DK (1) DK2461830T3 (en)
EA (1) EA022288B1 (en)
ES (1) ES2525351T3 (en)
HK (1) HK1164751A1 (en)
HR (1) HRP20140976T1 (en)
HU (1) HUE026997T2 (en)
IL (1) IL217717A (en)
IN (1) IN2012DN00860A (en)
MX (1) MX2012001665A (en)
NZ (1) NZ597985A (en)
PE (1) PE20121087A1 (en)
PL (1) PL2461830T3 (en)
PT (1) PT2461830E (en)
SG (2) SG10201503332XA (en)
SI (1) SI2461830T1 (en)
SM (1) SMT201400183B (en)
TW (1) TWI469794B (en)
WO (1) WO2011017249A1 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (en) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド Bivalent linker and conjugate thereof
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
IT1394860B1 (en) * 2009-07-22 2012-07-20 Kemotech S R L PHARMACEUTICAL COMPOUNDS
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN114246952A (en) 2010-06-08 2022-03-29 基因泰克公司 Cysteine engineered antibodies and conjugates
EP2686334B2 (en) * 2011-03-16 2020-07-01 F.Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP3925627A1 (en) * 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
HUE048574T2 (en) * 2012-07-12 2020-08-28 Hangzhou Dac Biotech Co Ltd Conjugates of cell binding molecules with cytotoxic agents
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
EP2708243A1 (en) 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
IN2015DN04147A (en) 2012-10-16 2015-10-16 Endocyte Inc
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
JP6133431B2 (en) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Use of hydrophilic conjugates and conjugation reactions between drug molecules and cell binding molecules
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
WO2014126836A1 (en) 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
US20140249315A1 (en) * 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
PT2968440T (en) 2013-03-15 2019-07-31 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6171435B2 (en) * 2013-03-18 2017-08-02 富士通株式会社 Semiconductor device and manufacturing method thereof, power supply device, and high-frequency amplifier
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
WO2015057585A1 (en) * 2013-10-14 2015-04-23 Regents Of The University Of Minnesota Therapeutic compounds
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
US20170168074A1 (en) 2013-11-25 2017-06-15 Ontochem Gmbh Method for diagnosing G-protein coupled receptor-related diseases
ES2916722T3 (en) 2013-12-27 2022-07-05 Zymeworks Inc Sulfonamide-containing linkage systems for drug conjugates
MX2016008448A (en) 2013-12-27 2017-01-09 Zymeworks Inc Var2csa-drug conjugates.
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
WO2015135659A1 (en) 2014-03-14 2015-09-17 Ontochem Gmbh Receptor ligand linked cytotoxic molecules
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
KR20160142392A (en) * 2014-04-11 2016-12-12 메디뮨 엘엘씨 Tubulysin derivatives
CA2951049C (en) * 2014-06-03 2023-01-03 Jiarui Biopharmaceuticals, Ltd. Peptide-drug conjugates
CA2958495C (en) 2014-08-22 2023-04-18 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof
CN104262455B (en) * 2014-08-22 2017-05-03 亚飞（上海）生物医药科技有限公司 Tumor microenvironment targeted activation docetaxel derivatives, preparation thereof and uses of the derivatives
JP6473226B2 (en) * 2014-09-11 2019-02-20 シアトル ジェネティックス， インコーポレイテッド Targeted delivery of tertiary amine-containing drug substances
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR102569813B1 (en) 2014-11-21 2023-08-24 브리스톨-마이어스 스큅 컴퍼니 Antibodies against cd73 and uses thereof
ES2822990T3 (en) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novel PD-L1 Binding Polypeptides for Imaging
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CA2977589A1 (en) * 2015-02-25 2016-09-01 William Marsh Rice University Desacetoxytubulysin h and analogs thereof
WO2016144608A1 (en) 2015-03-10 2016-09-15 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
ES2809125T3 (en) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Glypican-3 binding fibronectin-based scaffold molecules
US11730009B2 (en) * 2015-09-24 2023-08-15 Lg Chem, Ltd. Compound and organic light-emitting element comprising same
TWI660741B (en) 2015-11-03 2019-06-01 財團法人工業技術研究院 Antibody-drug conjugate (adc) and method for forming the same
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20180089433A (en) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 Variant antibodies for site-specific conjugation
EP3411371A1 (en) 2016-02-01 2018-12-12 Pfizer Inc Tubulysin analogs and methods for their preparation
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CN105664134B (en) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 It is a kind of for treating the pharmaceutical composition of osteocarcinoma
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
KR20190005924A (en) * 2016-05-10 2019-01-16 브리스톨-마이어스 스큅 컴퍼니 Antibody-drug conjugates of tuburicin analogs with improved stability
WO2017218724A1 (en) 2016-06-16 2017-12-21 Bristol-Myers Squibb Company Process and intermediates for making tubulysin analogs
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
KR20220147720A (en) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
JP6585650B2 (en) * 2017-03-23 2019-10-02 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド Conjugates of cytotoxic agents and cell-bound receptors
CA3064321A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2019108685A1 (en) * 2017-11-29 2019-06-06 William March Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
AU2019277094A1 (en) 2018-05-29 2021-01-21 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US11020490B2 (en) 2018-06-22 2021-06-01 Bristol-Myers Squibb Company Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7389803B2 (en) 2018-11-30 2023-11-30 ブリストル－マイヤーズ スクイブ カンパニー Antibodies containing an elongated portion at the C-terminus of a light chain containing glutamine, conjugates thereof, and methods and uses thereof
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
US20210260208A1 (en) 2018-12-21 2021-08-26 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP6842127B2 (en) * 2019-05-22 2021-03-17 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド Conjugates of cytotoxic agents and cell-binding receptors
KR20220029725A (en) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 Cell-binding molecule-tubulin derivative conjugate and method for preparing same
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
CN113387829B (en) * 2020-03-13 2023-04-07 凯特立斯（深圳）科技有限公司 Preparation method of shakubiqu
EP4171653A2 (en) * 2020-06-24 2023-05-03 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP7044419B2 (en) * 2021-02-04 2022-03-30 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド Conjugates of cytotoxic agents and cell-binding receptors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
TW420681B (en) 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
DE19638870B4 (en) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysins, methods for their production and agents containing them
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DE10008089A1 (en) 2000-02-22 2001-10-31 Biotechnolog Forschung Gmbh Production of tubulysin compounds comprises multi-stage process including condensation of N-methylpipecolinoyl-isoleucine with substituted thiazole-4-carboxylic acid derivative
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
KR20030033007A (en) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7387776B2 (en) * 2002-01-09 2008-06-17 Medarex, Inc. Human monoclonal antibodies against CD30
US7816377B2 (en) * 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
EP1521769B1 (en) * 2002-07-09 2015-09-09 Dömling, Alexander Tubulysin conjugates
DE10241152A1 (en) * 2002-09-05 2004-03-18 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysin biosynthesis genes
FR2845630B1 (en) * 2002-10-09 2005-09-30 Helitest Ags DEMASTICATING DEVICE, IN PARTICULAR FOR REFLECTING JOINTS IN AIRCRAFT TANK STRUCTURES AND CONTAINER INTERVENTION
DE10254439A1 (en) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysins, manufacturing processes and tubulysin agents
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
NZ544911A (en) * 2003-07-22 2008-12-24 Schering Ag RG1 antibodies and uses thereof
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2564076C (en) * 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
DE102004030227A1 (en) 2004-06-23 2006-01-26 Dömling, Alexander, Dr. Treatment of diseases (e.g. proliferative diseases of tumor cells, ophthalmic diseases and skin diseases) associated with angiogenesis comprises administration of carbamide compounds
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
CN101124249B (en) * 2005-02-18 2011-06-29 米德列斯公司 Human monoclonal antibodies to prostate specific membrane antigen(PSMA)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006262232A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
BRPI0615354A2 (en) * 2005-08-19 2011-05-17 Endocyte Inc receptor binding drug release conjugate, pharmaceutical composition comprising it, as well as its use
BRPI0617546A2 (en) * 2005-09-26 2011-07-26 Medarex Inc drug-antibody conjugate, pharmaceutical formulation, method for killing a tumor cell, method for retarding or arresting tumor growth in a mammalian subject and compound
ES2527961T3 (en) * 2005-09-26 2015-02-02 Medarex, L.L.C. Human monoclonal antibodies to CD70
CA2627046C (en) * 2005-10-26 2015-09-15 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
CA2627190A1 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
SI1957539T1 (en) * 2005-12-08 2013-05-31 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
EP1963371A2 (en) * 2005-12-08 2008-09-03 Medarex Inc. Human monoclonal antibodies to o8e
BRPI0717902A2 (en) 2006-12-01 2013-10-29 Medarex Inc "HUMAN MONOCLONAL ANTIBODY ISOLATED, COMPOSITION, ASSOCIATED ANTIBODY-MOLLECLE PARTNERSHIP, IMMUNOCOUGHTED, ISOLATED NUCLEIC ACID MOLECULES, EXPRESSION VECTOR, HOSPEDIC CELL FOR PREPARING A CDT FOR THE PREPARATION OF A CD22 AND METHOD FOR TREATING INFLAMMATORY DISEASE OR SELF-IMMUNEING AN INDIVIDUAL "
MX2009006277A (en) 2006-12-14 2009-07-24 Medarex Inc Human antibodies that bind cd70 and uses thereof.
UY30776A1 (en) * 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
JP2010516625A (en) * 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
TW200900059A (en) * 2007-02-21 2009-01-01 Medarex Inc Chemical linkers with single amino acids and conjugates thereof
WO2008106080A2 (en) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
NZ599239A (en) * 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
EP2148886B1 (en) 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US7387981B1 (en) 2007-06-28 2008-06-17 Lyondell Chemical Technology, L.P. Direct epoxidation catalyst and process
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
EP2174947A1 (en) * 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011057805A1 (en) * 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors

Also Published As

Publication number Publication date
HK1164751A1 (en) 2012-09-28
US20110027274A1 (en) 2011-02-03
IL217717A0 (en) 2012-03-29
TW201106976A (en) 2011-03-01
WO2011017249A1 (en) 2011-02-10
US20160060294A1 (en) 2016-03-03
AR077701A1 (en) 2011-09-14
MX2012001665A (en) 2012-03-26
JP5859964B2 (en) 2016-02-16
BR112012002615A2 (en) 2020-11-03
PL2461830T3 (en) 2015-03-31
US20140323690A1 (en) 2014-10-30
US8802632B2 (en) 2014-08-12
HUE026997T2 (en) 2016-08-29
CN104592351A (en) 2015-05-06
US9580467B2 (en) 2017-02-28
EA201270242A1 (en) 2012-07-30
US8772543B2 (en) 2014-07-08
US8772542B2 (en) 2014-07-08
EP2461830A1 (en) 2012-06-13
CA2770042A1 (en) 2011-02-10
AU2010279674A1 (en) 2012-02-23
KR20120047998A (en) 2012-05-14
EP2461830B1 (en) 2014-09-24
PE20121087A1 (en) 2012-08-17
CL2012000302A1 (en) 2012-07-20
CN102725001B (en) 2015-01-14
SI2461830T1 (en) 2015-01-30
US20130204033A1 (en) 2013-08-08
SMT201400183B (en) 2015-01-15
HRP20140976T1 (en) 2015-01-02
EA022288B1 (en) 2015-12-30
PT2461830E (en) 2014-12-11
US20130189256A1 (en) 2013-07-25
NZ597985A (en) 2013-08-30
US9226974B2 (en) 2016-01-05
US8394922B2 (en) 2013-03-12
SG10201503332XA (en) 2015-06-29
SG178095A1 (en) 2012-03-29
CO6501196A2 (en) 2012-08-15
TWI469794B (en) 2015-01-21
JP2013501055A (en) 2013-01-10
DK2461830T3 (en) 2015-01-12
CN102725001A (en) 2012-10-10
US20130197259A1 (en) 2013-08-01
ES2525351T3 (en) 2014-12-22
CA2770042C (en) 2017-02-28
AU2010279674B2 (en) 2015-05-07
KR101759359B1 (en) 2017-07-18
IL217717A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IN2012DN00860A (en)
MX341524B (en) Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates.
NZ705394A (en) Antibody-drug conjugate
MX341133B (en) Compounds and methods.
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
AU2013291345B2 (en) Composition for controlling plant disease and application therefor
EA201591317A1 (en) COMPOUNDS OF TUBULIZIN, METHODS OF THEIR RECEPTION AND APPLICATION
TW200940681A (en) Novel organic electroluminescent compounds and organic electroluminescent device using the same
MX2010004493A (en) Tropane compounds.
IN2015MN00135A (en)
EA201170168A1 (en) COMPLEX (MINERAL-AMINO ACID) - POLYSACCHARIDE
MX2012008141A (en) Compounds and methods.
EA201200102A1 (en) COMPOUNDS APPLICABLE AS A MEDICINE
RS52255B (en) Nalmefene hydrochloride dihydrate
EA201170154A1 (en) DERIVATIVES OF PYRIDINOPIRIDINONES, METHOD OF THEIR RECEPTION AND APPLICATION IN THERAPY
MX340870B (en) Iap bir domain binding compounds.
MX2013008560A (en) Method for preparing 2-aminobenzamide derivatives.
MX349373B (en) Novel pyrazine derivatives.
HK1124842A1 (en) Methods of preparing imidazole-based compounds
MX2012007835A (en) 2,5,7-substituted oxazolopyrimidine derivatives.
EA201270237A1 (en) Method of producing 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and necessary intermediate compounds containing magnetic
MX2012012523A (en) Anticancer steroidal lactones unsaturated in position 7 (8).
MX2012005155A (en) Quinazoline compounds.
EA201300792A1 (en) CHEMICAL COMPOUNDS
MX2012014796A (en) Process for preparing 4-hydroxypyridines.